[Contribution of B lymphocytes in acquired resistance to targeted therapies in metastatic melanoma]

Med Sci (Paris). 2018 Oct;34(10):875-878. doi: 10.1051/medsci/2018219. Epub 2018 Nov 19.

[Article in French]

Authors

Camille Fourneaux¹, Bertrand Dubois²

Affiliations

¹ Master 1 Cancer, module d'immunologie-virologie, université de Lyon, université Claude Bernard Lyon 1, Lyon, France.
² UMR Inserm 1052 CNRS 5286, centre Léon Bérard, centre de recherche en cancérologie de Lyon, 28, rue Laennec 69373 Lyon Cedex 08, France.

PMID: 30451659
DOI: 10.1051/medsci/2018219

No abstract available

Publication types

News

MeSH terms

B-Lymphocytes / physiology*
Drug Resistance, Neoplasm / immunology*
Humans
Immunotherapy / adverse effects
Melanoma / immunology
Melanoma / pathology
Melanoma / therapy*
Molecular Targeted Therapy*
Neoplasm Metastasis
Skin Neoplasms / immunology
Skin Neoplasms / pathology
Skin Neoplasms / therapy*
Treatment Failure